Risks

Weak near-term liquidity versus larger biotech peers, with a current ratio below 1.0, increases refinancing and working-capital pressure if development timelines slip.

Negative interest coverage and negative net debt to EBITDA indicate limited earnings support for obligations, leaving CPIX more exposed than cash-generative peers.

Very long receivables collection versus peers can delay cash conversion, which may constrain funding flexibility and amplify dilution risk if capital markets tighten.

Extremely extended payables suggest reliance on supplier financing, which can support liquidity short term but may strain vendor terms relative to better-capitalized peers.

Opportunities

Low debt-to-equity and modest net debt versus peers preserve balance-sheet optionality, which can support clinical execution if capital access remains available.

Negative net debt to EBITDA indicates limited leverage burden, so any operating improvement could translate more quickly into financing flexibility than at more indebted peers.

Efficient inventory management versus peers reduces tied-up capital, which can partially offset weak receivables collection and support runway preservation.

If development progress improves, CPIX’s lighter leverage profile could allow a sharper re-rating than peers carrying heavier debt loads and higher fixed claims.

Overall Score

CPIX’s forward positioning is constrained mainly by liquidity and cash-conversion pressure, while modest leverage and limited debt burden provide some offset versus more indebted peers.